Author

M. Pule

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

J. Sillibourne· 3 shared C. Allen· 2 shared E. Kokalaki· 2 shared I. Gannon· 2 shared M. Ferrari· 2 shared M. Robson· 2 shared S. Srivastava· 2 shared S. Thomas· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

J. Sillibourne

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Exploration of T-cell immune responses by expression of a dominant-negative SHP1 and SHP2

J. Taylor, A. Bulek, I. Gannon, M. Robson, E. Kokalaki, T. Grothier, C. McKenzie, M. El-Kholy, M. Stavrou, C. Traynor-White, W. C. Lim, P. Panagiotou, S. Srivastava, V. Baldan, J. Sillibourne, , S. Thomas

This study investigates the role of SHP1 and SHP2 in T-cell immunosuppression by expressing truncated variants and shows that dSHP2 can alleviate PD1-mediated suppression in CAR T cells.

bioRxiv · Apr 26, 2023Immunology

Enhancing CAR T cell therapy using Fab-Based Constitutively Heterodimeric Cytokine Receptors

M. Righi, I. Gannon, M. Robson, S. Srivastava, E. Kokalaki, T. Grothier, F. Nannini, C. Allen, B. Yuchen, J. Sillibourne, S. P. Cordoba, S. Thomas, M. Pule

This paper introduces a dimerization domain from IgG1 antibodies to create engineered cytokine receptors that mimic natural heterodimerization, enhancing CAR T cell therapy efficacy.

bioRxiv · Apr 24, 2023Immunology

Characterisation of a novel ACE2-based therapeutic with enhanced rather than reduced activity against SARS-CoV2 variants

M. Ferrari, L. Mekkaoui, F. T. Ilca, Z. Akbar, R. Bughda, K. Lamb, K. Ward, F. Parekh, R. Karattil, C. Allen, P. Wu, V. Baldan, G. Mattiuzzo, E. M. Bentley, Y. Takeuchi, , S. Onuoha

The paper characterizes a novel ACE2-based therapeutic that effectively neutralizes SARS-CoV-2 variants and demonstrates antibody-like properties and manufacturability.

bioRxiv · Mar 17, 2021Immunology